The company provides a technology platform that helps in the production of progenitor blood and immune cells for clinical application, using a proprietary stem cell expansion and directed-differentiation platform. This platform can generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases. Deverra Therapeutics is a clinical stage biotechnology company with an exclusive license to this technology from the Fred Hutchinson Cancer Research Center.